Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether statin could prevent recurrence of hepatocellular carcinoma after curative treatment

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chiayi Christian Hospital
• Collaborators: Chi Mei Medical Hospital; E-DA Hospital; Mackay Memorial Hospital; National Cheng-Kung University Hospital; National Taiwan University Hospital; Taichung Veterans General Hospital; Tainan Municipal Hospital
• Treatments: Atorvastatin; Atorvastatin Calcium; Hydroxymethylglutaryl-CoA Reductase Inhibitors

Criteria

Inclusion Criteria:

• Individuals with HCC BCLC stage 0 or A who received curative radiofrequency ablation or hepatic resection could be eligible.

• Individuals who had single HCC (size > 5.0 cm) received hepatic resection would be eligible

• Individuals with prior history of HCC who had ever received curative ablation or hepatic resection without any recurrence for more than 2 years could be eligible if they had a new episode of recurrent HCC which could meet either of the former two criteria.

• After 12+/-1 weeks of curative treatment, eligible patients who have no evidence of local residual or recurrent tumors according to the dynamic CT or MRI could be enrolled

• The diagnosis of fresh HCC should be compatible with either pathological report or meet the criteria of AASLD guidelines

Exclusion Criteria:

• Undetermined nature of hepatic tumor

• HCC with extrahepatic metastasis or major vascular invasion

• With other malignant disease

• Child Pugh score >7

• Previous history of CAD event (angina, unstable angina, acute myocardial infarction) or ischemic stroke

• Hyperlipidemia or other indication for statin (according to Taiwan NHI guideline)

• Advanced CKD (eGFR<30) or ESRD

• Severe comorbidity with life expectancy < 2 years

• Allergy to statin